Project Grant R37CA309508
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $730K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charlottesville, VA 22904, USA
Similar Awards
- The National Cancer Institute awarded the University of Virginia $161,500 for cancer cell biology research on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396). The project develops methods to classify pancreatic ductal adenocarcinoma circulating tumor cells by single-cell deformability. Researchers will create a perfusable co-culture system with cancer-associated fibroblasts to generate pancreatic cancer cells expressing varied epithelial and mesenchymal states under shear...
- The National Cancer Institute awarded Northeastern University $224,400 under the Cancer Biology Research program (CFDA 93.396) on August 1, 2026, to develop a direct RNA sequencing platform that detects dihydrouridine (D) modifications in human lung cancer transcripts at transcriptome-wide, single-nucleotide resolution. Current technologies cannot reliably distinguish dihydrouridine from pseudouridine and uridine, limiting understanding of how uridine modifications regulate RNA biology in...
- The National Cancer Institute awarded The Trustees of Columbia University in the City of New York $532,627 for research on tumor suppressive functions of SMARCA4 in lung cancer, effective September 1, 2026, under the Cancer Biology Research program (CFDA 93.396). The award funds a five-year project (through August 31, 2031) conducted at Columbia's Health Sciences Division in New York, New York. The research develops and employs genetically engineered mouse models of SMARCA4-deficient lung...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $415,259 to the Rector & Visitors of the University of Virginia to conduct research on the role of long noncoding RNAs in acute myeloid leukemia (AML). The project aims to 1) determine the role of a specific regulatory RNA in primary and relapsed AML, and 2) define the mechanism underlying its deregulation in AML. This research will provide insights into how noncoding RNAs...
- The National Cancer Institute awarded $546,542 to the Centre International de Recherche sur le Cancer (IARC) on August 11, 2026, to develop a proteogenomic framework for precision lung cancer screening under the Cancer Cause and Prevention Research program (CFDA 93.393). The project refines the INTEGRAL protein risk model, a 13-marker assay designed to improve lung cancer screening eligibility assessment and nodule management following low-dose computed tomography. The existing INTEGRAL model...
- The National Cancer Institute awarded the University of Virginia $529,456 on August 5, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate how inhibition of the ufmylation protein pathway enhances anti-tumor immunity and converts immunologically cold tumors into responsive ones. The project uses genetic and chemical inhibitors of the UBA5 protein—a key component of the ufmylation posttranslational modification pathway—to test whether ufmylation inhibition reduces...
- The National Cancer Institute awarded The Leland Stanford Junior University $635,340 on May 4, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct functional genomic dissection of lung cancer in vivo. Stanford will integrate genetically engineered mouse models, multiplexed CRISPR-based genome editing, and tumor barcoding to assess tumor suppressor gene function across multiple genotypes and their effects on lung tumor initiation and growth in parallel. In Aim 1,...
- The National Cancer Institute awarded The Washington University $425,088 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to evaluate the delivery and quality of lung cancer care among older adults enrolled in Medicare Advantage versus traditional Medicare. The research examines disparities in lung cancer screening, diagnosis, treatment patterns, and clinical outcomes across these two insurance programs. The project compares guideline-concordant treatment...
- The National Cancer Institute awarded the University of Virginia $192,887 on May 8, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research on sphingolipid-guided stratification and therapeutic opportunities in acute myeloid leukemia. The project investigates sphingolipid metabolism as a mechanism to improve acute myeloid leukemia risk classification beyond genomic characterization. Prior work identified two AML patient subtypes distinguished by reciprocal abundance of...
- The National Cancer Institute awarded MD Anderson Cancer Center $669,540 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to elucidate the roles of the CD24 ligand in early lung cancer development, immune evasion, and response to KRAS-targeted therapy. The research investigates CD24 signaling in KRAS-mutant lung adenocarcinomas (KM-LUADs), which account for approximately 30 percent of lung adenocarcinomas in lifetime smokers. Preliminary findings indicate CD24 elevation...